We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest trading session, Amgen (AMGN - Free Report) closed at $349.69, marking a +1.43% move from the previous day. This move outpaced the S&P 500's daily gain of 0.5%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq increased by 0.43%.
The world's largest biotech drugmaker's stock has climbed by 3.55% in the past month, exceeding the Medical sector's loss of 0.63% and the S&P 500's gain of 0.18%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 3, 2026. It is anticipated that the company will report an EPS of $4.74, marking a 10.73% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $9.46 billion, reflecting a 4.16% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $21.27 per share and a revenue of $36.35 billion, demonstrating changes of +7.21% and 0%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.22% higher. Right now, Amgen possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, Amgen is currently exchanging hands at a Forward P/E ratio of 15.86. Its industry sports an average Forward P/E of 20.09, so one might conclude that Amgen is trading at a discount comparatively.
We can additionally observe that AMGN currently boasts a PEG ratio of 3.06. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.45 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Laps the Stock Market: Here's Why
In the latest trading session, Amgen (AMGN - Free Report) closed at $349.69, marking a +1.43% move from the previous day. This move outpaced the S&P 500's daily gain of 0.5%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq increased by 0.43%.
The world's largest biotech drugmaker's stock has climbed by 3.55% in the past month, exceeding the Medical sector's loss of 0.63% and the S&P 500's gain of 0.18%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 3, 2026. It is anticipated that the company will report an EPS of $4.74, marking a 10.73% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $9.46 billion, reflecting a 4.16% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $21.27 per share and a revenue of $36.35 billion, demonstrating changes of +7.21% and 0%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.22% higher. Right now, Amgen possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, Amgen is currently exchanging hands at a Forward P/E ratio of 15.86. Its industry sports an average Forward P/E of 20.09, so one might conclude that Amgen is trading at a discount comparatively.
We can additionally observe that AMGN currently boasts a PEG ratio of 3.06. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.45 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 36% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.